We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+6.62%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$869B
AUM Growth
+$32.9B
Cap. Flow
-$6.92B
Cap. Flow %
-0.8%
Top 10 Hldgs %
33.83%
Holding
3,059
New
82
Increased
1,782
Reduced
864
Closed
51

Top Buys

Rank Stock Value
1
AMD icon
Advanced Micro Devices
AMD
+$2.31B
2
AAPL icon
Apple
AAPL
+$1.58B
3
SHW icon
Sherwin-Williams
SHW
+$1.37B
4
HUBS icon
HubSpot
HUBS
+$1.32B
5
KVUE icon
Kenvue
KVUE
+$1.25B

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$4.37B
2
LRCX icon
Lam Research
LRCX
+$1.54B
3
AMAT icon
Applied Materials
AMAT
+$1.33B
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.19B
5
HAL icon
Halliburton
HAL
+$1.16B

Sector Composition

Rank Sector Weight
1 Technology 32.32%
2 Healthcare 15.15%
3 Financials 10.54%
4 Consumer Discretionary 10.48%
5 Communication Services 8.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VTYX
2776
DELISTED
Ventyx Biosciences
VTYX
$120K ﹤0.01%
54,902
+2,169
+4% +$4.99K
AQST icon
2777
Aquestive Therapeutics
AQST
$531M
$119K ﹤0.01%
23,848
KG
2778
Kestrel Group
KG
$66.3M
$119K ﹤0.01%
3,346
PPTA
2779
Perpetua Resources
PPTA
$3.16B
$119K ﹤0.01%
12,655
+358
+3% +$2.66K
ADV icon
2780
Advantage Solutions
ADV
$399M
$118K ﹤0.01%
1,369
MURA
2781
DELISTED
Mural Oncology
MURA
$118K ﹤0.01%
37,674
AGEN
2782
Agenus
AGEN
$311M
$116K ﹤0.01%
21,072
+231
+1% +$1.73K
SLRN
2783
DELISTED
ACELYRIN
SLRN
$116K ﹤0.01%
23,472
+528
+2% +$2.73K
VOXX
2784
DELISTED
VOXX International Corporation Class A
VOXX
$116K ﹤0.01%
18,200
QURE icon
2785
uniQure
QURE
$3.13B
$115K ﹤0.01%
23,300
KPTI icon
2786
Karyopharm Therapeutics
KPTI
$46M
$112K ﹤0.01%
8,980
+2,507
+39% +$31.2K
STTK icon
2787
Shattuck Labs
STTK
$752M
$112K ﹤0.01%
31,903
EVC icon
2788
Entravision Communication
EVC
$832M
$111K ﹤0.01%
53,197
-1,234
-2% -$2.46K
UPLD icon
2789
Upland Software
UPLD
$14.9M
$110K ﹤0.01%
4,400
TUSK icon
2790
Mammoth Energy Services
TUSK
$158M
$109K ﹤0.01%
26,473
+2,042
+8% +$7.47K
CMTL icon
2791
Comtech Telecommunications
CMTL
$52.1M
$108K ﹤0.01%
22,443
LILA icon
2792
Liberty Latin America Class A
LILA
$1.69B
$107K ﹤0.01%
16,311
SMRT icon
2793
SmartRent
SMRT
$278M
$107K ﹤0.01%
61,814
LIND icon
2794
Lindblad Expeditions
LIND
$2.24B
$106K ﹤0.01%
11,381
+250
+2% +$2.32K
NNOX icon
2795
Nano X Imaging
NNOX
$75.8M
$106K ﹤0.01%
17,332
FOSL icon
2796
Fossil Group
FOSL
$311M
$105K ﹤0.01%
88,900
OLPX
2797
DELISTED
Olaplex Holdings
OLPX
$105K ﹤0.01%
44,462
QVCGA
2798
DELISTED
QVC Group Inc Series A
QVCGA
$105K ﹤0.01%
3,417
+1,392
+69% +$44.2K
ITI
2799
DELISTED
Iteris, Inc.
ITI
$105K ﹤0.01%
14,670
+2,216
+18% +$13.2K
STEM icon
2800
Stem
STEM
$48.8M
$104K ﹤0.01%
14,902
+6,595
+79% +$104K

Similar funds

T. Rowe Price Associates's Q3 2024 Portfolio in Review

As of Q3 2024, T. Rowe Price Associates held 3,059 positions worth $869B, up 3.9% from $836B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Trading was light in Q3 2024: portfolio turnover was 4.3%. T. Rowe Price Associates opened 82 new positions and exited 51, leaving the 3,059-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 34% a quarter earlier, followed by Healthcare and Financials.

  • T. Rowe Price Associates's largest Q3 2024 buy was Lineage Inc: 4,699,854 shares worth $368M.
  • T. Rowe Price Associates added most to Advanced Micro Devices in Q3 2024, an estimated $2.31B increase.
  • T. Rowe Price Associates's biggest Q3 2024 reduction was NVIDIA, cutting an estimated $4.37B.
  • T. Rowe Price Associates fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $75.2M.
  • T. Rowe Price Associates's ten largest holdings make up 34% of its $869B portfolio in Q3 2024.
  • T. Rowe Price Associates opened 82 new positions and closed 51 in Q3 2024.
  • T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $869B.

Based on T. Rowe Price Associates's 13F filing for Q3 2024, filed 14 Nov 2024.